نتائج البحث - "Domenico Magro"

1

Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives

المؤلفون: Nicola Vianelli, Giuseppe Auteri, Francesco Buccisano, Valentina Carrai, Erminia Baldacci, Cristina Clissa, Daniela Bartoletti, Gaetano Giuffrida, Domenico Magro, Elena Rivolti, Daniela Esposito, Gian Marco Podda, Francesca Palandri

المصدر: Annals of hematology. 101(5)

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f897b315f8687ccaf8312716d0895357
https://pubmed.ncbi.nlm.nih.gov/35201417

Find this article in full text from Springer Verlag.

Find this article in full text from ProQuest

2

MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine

المساهمون: Visani, G, Loscocco, F, Ruzzo, A, Galimberti, S, Graziano, F, Voso, M T, Giacomini, E, Finelli, C, Ciabatti, E, Fabiani, E, Barulli, S, Volpe, A, Magro, D, Piccaluga, P, Fuligni, F, Vignetti, M, Fazi, P, Piciocchi, A, Gabucci, E, Rocchi, M, Magnani, M, Isidori, A

مصطلحات موضوعية: Oncology, Male, medicine.medical_specialty, Palliative care, Genotype, Azacitidine, Single-nucleotide polymorphism, Thymidylate synthase, Polymorphism, Single Nucleotide, 03 medical and health sciences, XRCC1, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Genetics, medicine, Humans, Genetic Association Studies, Methylenetetrahydrofolate Reductase (NADPH2), Aged, Pharmacology, MTHFR, MDS, SNPs, biology, business.industry, Myelodysplastic syndromes, Palliative Care, Thymidylate Synthase, Middle Aged, medicine.disease, X-ray Repair Cross Complementing Protein 1, International Prognostic Scoring System, 030220 oncology & carcinogenesis, Methylenetetrahydrofolate reductase, Myelodysplastic Syndromes, biology.protein, Molecular Medicine, Female, business, Settore MED/15 - Malattie del Sangue, 030215 immunology, medicine.drug

وصف الملف: ELETTRONICO

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6470280dc7a8b7b0a93c31dd356cfdce
http://hdl.handle.net/11568/942981

3

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial

المصدر: Journal of Clinical Oncology, 34, 972-9
Journal of Clinical Oncology, 34, 9, pp. 972-9

مصطلحات موضوعية: 0301 basic medicine, Myeloid, Male, Cancer Research, Pediatrics, medicine.medical_specialty, Randomization, Gemtuzumab ozogamicin, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], CD33, Antineoplastic Agents, Enasidenib, Acute, Antibodies, Monoclonal, Humanized, Age Factors, Aged, Aged, 80 and over, Aminoglycosides, Female, Humans, Hydroxyurea, Leukemia, Myeloid, Acute, Middle Aged, Antibodies, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Monoclonal, Clinical endpoint, medicine, 80 and over, Humanized, Leukemia, business.industry, Hazard ratio, Myeloid leukemia, Gemtuzumab, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, business, Settore MED/15 - Malattie del Sangue, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd4694efdaeb2532521ee5bbc81345b3
http://hdl.handle.net/2108/162799

4

Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edf3bff9f6fdd7253ec73dd5abc1c0ed
http://hdl.handle.net/11568/820799

5

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial

المصدر: Journal of clinical oncology
Journal of Clinical Oncology, 32, 219-28
Journal of Clinical Oncology, 32, 3, pp. 219-28
Journal of Clinical Oncology, 32(3), 219

مصطلحات موضوعية: Oncology, Myeloid, Male, Cancer Research, Antimetabolites, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Adolescent, Adult, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Consolidation Chemotherapy, Cytarabine, Daunorubicin, Drug Administration Schedule, Etoposide, Europe, Female, Humans, Induction Chemotherapy, Infusions, Intravenous, Leukemia, Myeloid, Acute, Middle Aged, Mutation, Risk Assessment, Risk Factors, Treatment Outcome, AML, Leukemia, Medicine (all), Myeloid leukemia, Antineoplastic, medicine.anatomical_structure, Intravenous, medicine.drug, SD-ARAC, medicine.medical_specialty, Infusions, Acute, HD-ARAC, Internal medicine, medicine, HD cytarabine, business.industry, Induction chemotherapy, medicine.disease, Surgery, Human medicine, business, Settore MED/15 - Malattie del Sangue

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5a154e426dc98008efce3a2e903da8b
http://hdl.handle.net/2108/86228

6

Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17)

المصدر: Journal of Clinical Oncology, 31(35), 4424
Journal of clinical oncology
Journal of Clinical Oncology, 31, 4424-30
Journal of Clinical Oncology, 31, 35, pp. 4424-30

مصطلحات موضوعية: Male, Cancer Research, medicine.medical_treatment, chemotherapy, AML, Antineoplastic Combined Chemotherapy Protocols, Medicine, Etoposide, Remission Induction, Hazard ratio, Cytarabine, Translational research Immune Regulation [ONCOL 3], Induction Chemotherapy, Middle Aged, Gemtuzumab, Treatment Outcome, Liver, Oncology, Leukemia, Myeloid, GO, Go/no go, Acute Disease, Female, medicine.drug, medicine.medical_specialty, Gemtuzumab ozogamicin, Antibodies, Monoclonal, Humanized, Infections, Drug Administration Schedule, Mylotarg, karyotype, CD33 esxpression, Translational research [ONCOL 3], Internal medicine, Humans, Aged, Febrile Neutropenia, Chemotherapy, Mitoxantrone, business.industry, Induction chemotherapy, Survival Analysis, Surgery, Aminoglycosides, Human medicine, business, Settore MED/15 - Malattie del Sangue, Follow-Up Studies